HAVCR2 and melanoma: The information reinforced that Tim-3 was mediated by stimulating TCR signaling to STAT3 pathways during PD-1 blockade in melanoma, providing further support for combination STAT3 inhibitor and anti-PD-1 therapy for patients suffering from melanoma.